Glucagon-Like Peptide-1 Receptor Agonists-How Safe Are They?

JAMA Intern Med. 2022 May 1;182(5):520-521. doi: 10.1001/jamainternmed.2022.0335.

Authors

Shanzay Haider¹, Kasia J Lipska¹

Affiliation

¹ Department of Internal Medicine, Section of Endocrinology, Yale School of Medicine, New Haven, Connecticut.

PMID: 35344015
DOI: 10.1001/jamainternmed.2022.0335

No abstract available

Publication types

Comment

MeSH terms

Diabetes Mellitus, Type 2* / drug therapy
Glucagon-Like Peptide-1 Receptor*
Humans
Hypoglycemic Agents / adverse effects
Liraglutide / adverse effects

Substances

Glucagon-Like Peptide-1 Receptor
Hypoglycemic Agents
Liraglutide